Meta-analysis reveals reduced cancer stem cell viability following targeted therapies in triple-negative breast cancer models, indicating promising potential for combination treatments.
Cancer stem cells (CSCs) drive chemoresistance, metastasis, and relapse in triple-negative breast cancer (TNBC), yet a comprehensive synthesis of targeted therapy evidence remains lacking. We systematically searched PubMed, Scopus, and Web of Science (2010–2025) and pooled effect sizes from 12 eligible studies (540 TNBC samples) using a random-effects model per PRISMA 2020 guidelines. CSC-targeted therapies significantly reduced CSC viability (SMD = −1.12; 95% CI: −1.45 to −0.79; p < 0.001), with combination approaches showing superior efficacy, moderate heterogeneity (I2 = 52%), and no publication bias, supporting further clinical trials to validate these promising preclinical strategies
No takes yet. Share an insight, caveat, or question.
Rebai et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: